|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.79 EUR | +0.84% |
|
+0.37% | +17.95% |
| 12-04 | Grifols achieves self-sufficiency in plasma-derived medicines in Egypt | RE |
| 12-03 | European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading | MT |
| Capitalization | 6.59B 7.73B 6.15B 5.79B 10.66B 700B 11.64B 71.81B 27.85B 330B 29.01B 28.4B 1,204B | P/E ratio 2025 * |
17.2x | P/E ratio 2026 * | 12.7x |
|---|---|---|---|---|---|
| Enterprise value | 15.53B 18.23B 14.51B 13.65B 25.13B 1,651B 27.45B 169B 65.67B 778B 68.39B 66.95B 2,839B | EV / Sales 2025 * |
2.07x | EV / Sales 2026 * | 1.92x |
| Free-Float |
79.4% | Yield 2025 * |
1.32% | Yield 2026 * | 1.86% |
Last Transcript: Grifols, S.A.
| 1 day | +0.84% | ||
| 1 week | +0.37% | ||
| Current month | +2.47% | ||
| 1 month | -1.28% | ||
| 3 months | -10.46% | ||
| 6 months | +5.84% | ||
| Current year | +17.95% |
| 1 week | 10.56 |  | 10.94 |
| 1 month | 9.91 | | 10.98 |
| Current year | 7.32 | | 13.7 |
| 1 year | 7.32 | | 13.7 |
| 3 years | 6.36 | | 15.92 |
| 5 years | 6.36 | | 26.07 |
| 10 years | 6.36 | | 34.31 |
| Manager | Title | Age | Since |
|---|---|---|---|
Nacho Abia
CEO | Chief Executive Officer | 57 | 31/03/2024 |
Jörg Schüttrumpf
CTO | Chief Tech/Sci/R&D Officer | 51 | 31/08/2024 |
| Comptroller/Controller/Auditor | 46 | 31/12/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 75 | 24/01/2010 | |
| Director/Board Member | 69 | 12/04/2000 | |
| Director/Board Member | 62 | 23/05/2015 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 0.98% | 154 M€ | +44.86% | - |
| 0.21% | 1,096 M€ | +30.14% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.84% | +0.37% | +15.35% | +2.32% | 7.73B | |
| -0.74% | +3.19% | +1.37% | -0.84% | 76.06B | |
| +2.86% | -0.09% | -33.73% | -38.08% | 58.96B | |
| +1.38% | +69.20% | +69.20% | +69.20% | 53.01B | |
| -2.24% | -4.93% | +30.25% | +221.80% | 52.48B | |
| +0.93% | -3.97% | +16.04% | -40.22% | 25.54B | |
| +1.85% | -7.39% | +127.81% | +163.37% | 18.76B | |
| -0.72% | -6.94% | +39.18% | +15.08% | 18.73B | |
| -4.52% | -5.15% | +36.59% | +1,036.48% | 15.67B | |
| +1.46% | +2.05% | +173.37% | +704.60% | 14.48B | |
| Average | +0.11% | -1.93% | +47.54% | +213.37% | 34.14B | |
| Weighted average by Cap. | +0.20% | -0.70% | +29.63% | +122.39% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 7.5B 8.81B 7.01B 6.59B 12.14B 798B 13.26B 81.81B 31.73B 376B 33.05B 32.35B 1,372B | 7.88B 9.25B 7.36B 6.93B 12.76B 838B 13.94B 85.96B 33.34B 395B 34.72B 33.99B 1,441B |
| Net income | 433M 508M 405M 381M 701M 46.06B 766M 4.72B 1.83B 21.71B 1.91B 1.87B 79.21B | 569M 668M 532M 500M 921M 60.54B 1.01B 6.21B 2.41B 28.54B 2.51B 2.46B 104B |
| Net Debt | 8.94B 10.5B 8.35B 7.86B 14.47B 951B 15.81B 97.5B 37.82B 448B 39.39B 38.56B 1,635B | 8.58B 10.08B 8.02B 7.54B 13.89B 913B 15.17B 93.6B 36.31B 430B 37.81B 37.01B 1,570B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/12/25 | 10.79 € | +0.84% | 935,815 |
| 11/12/25 | 10.70 € | -0.05% | 962,931 |
| 10/12/25 | 10.70 € | -0.19% | 628,001 |
| 09/12/25 | 10.72 € | -0.88% | 977,245 |
| 08/12/25 | 10.82 € | +0.65% | 1,046,968 |
Delayed Quote BME, December 12, 2025 at 04:35 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GRF Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition